PMID: 9425564Jan 13, 1998Paper

Management of spasticity

Current Opinion in Neurology
S Hesse, K H Mauritz

Abstract

Recent open studies and two placebo-controlled studies confirm the potential role of Botulinum toxin A in the treatment of focal spasticity in adults and children. The effect of the toxin might not only be mediated by the paresis of extrafusal, but also intrafusal muscle fibres, thereby altering the afferent discharge. To enhance its effectiveness, an additional electrical stimulation seems promising. Most patients tolerate the neurolytic agent well. Two individuals, however, suffered from an intermittent tetraparesis after treatment. The repetitive magnetic stimulation and the use of gabapentin might be other new therapeutic options in the management of spasticity.

Citations

Dec 8, 2005·Der Orthopäde·L Döderlein
May 18, 1999·Archives of Physical Medicine and Rehabilitation·F M Lin, M Sabbahi
Mar 18, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·M Zouhair Atassi
Apr 16, 2002·American Journal of Physical Medicine & Rehabilitation·Han-Cheng WangShih-Min Lou
Aug 21, 2013·Topics in Spinal Cord Injury Rehabilitation·Roberta DionelloDinuke R Warakaulle
Nov 11, 1999·Current Opinion in Neurology·A R Bentivoglio, A Albanese

❮ Previous
Next ❯

Related Concepts

Related Feeds

Botulism (ASM)

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.

Botulism

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.